BIOR Stock Overview
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Biora Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.64 |
| 52 Week High | US$6.70 |
| 52 Week Low | US$0.58 |
| Beta | 1.09 |
| 1 Month Change | -47.62% |
| 3 Month Change | -30.32% |
| 1 Year Change | -72.34% |
| 3 Year Change | -99.15% |
| 5 Year Change | n/a |
| Change since IPO | -99.81% |
Recent News & Updates
Recent updates
Biora Therapeutics granted patent for oral delivery of GLP-1 receptor agonists
Sep 13Biora Therapeutics: Checking In On The Transformation
Aug 17Biora rallies 30%, highest since November on data for drug delivery device
Aug 10Progenity: Analyzing The Huge Paradigm Shift
Dec 20Progenity: Transformation Raises Questions
Oct 03Progenity on a roller coaster ride since strategic transformation announcement
Jun 09Progenity presents new study data for preeclampsia rule-out Test
Apr 30Earnings Release: Here's Why Analysts Cut Their Progenity, Inc. (NASDAQ:PROG) Price Target To US$8.00
Mar 20
Is Progenity, Inc. (NASDAQ:PROG) Popular Amongst Insiders?
Mar 02Shareholder Returns
| BIOR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.5% | 1.5% | 1.2% |
| 1Y | -72.3% | 1.1% | 24.7% |
Return vs Industry: BIOR underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: BIOR underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| BIOR volatility | |
|---|---|
| BIOR Average Weekly Movement | 20.9% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIOR's share price has been volatile over the past 3 months.
Volatility Over Time: BIOR's weekly volatility has increased from 16% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 58 | Adi Mohanty | www.bioratherapeutics.com |
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company’s targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline.
Biora Therapeutics, Inc. Fundamentals Summary
| BIOR fundamental statistics | |
|---|---|
| Market cap | US$22.93m |
| Earnings (TTM) | -US$124.33m |
| Revenue (TTM) | US$4.00k |
5,732x
P/S Ratio-0.2x
P/E RatioIs BIOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOR income statement (TTM) | |
|---|---|
| Revenue | US$4.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$4.00k |
| Other Expenses | US$124.34m |
| Earnings | -US$124.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.46 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,108,350.00% |
| Debt/Equity Ratio | -45.5% |
How did BIOR perform over the long term?
See historical performance and comparison